Updated Nov 4, 2026FDA and CMS public dataIndependent · free · not health advice
GxRadar
Drugs/Gabapentin 300 mg capsule
Nerve pain / seizures

Gabapentin 300 mg capsule

Public data on gabapentin from CMS and FDA: what pharmacies have paid for it, how many generic applications FDA has approved, and whether it appears in FDA's shortage or recall records.

$0.0328
NADAC per ea (2026-11)
approximate acquisition cost, not a retail price
-36%
change over five years
peak $0.0630 in 2014-02
70
approved generic applications (ANDAs) on record for Gabapentin
44 with a product still marketed · first 2003
Not listed
in FDA's current shortage list
no matching FDA shortage entries

NADAC per unit, monthly

GABAPENTIN 300 MG CAPSULE
Show as table
MonthNADAC per unit ($)
2013-110.05637
2014-020.06302
2014-050.05636
2014-080.05217
2014-110.04671
2015-020.04924
2015-050.04978
2015-080.04692
2015-110.04470
2016-020.04461
2016-050.04372
2016-080.04659
2016-110.04073
2017-020.04131
2017-050.04049
2017-080.04212
2017-110.04034
2018-020.04325
2018-050.04382
2018-080.04719
2018-110.05717
2019-020.05351
2019-050.05115
2019-080.05394
2019-110.05572
2020-020.05454
2020-050.05791
2020-080.05498
2020-110.05120
2021-020.04967
2021-050.04988
2021-080.05091
2021-110.05098
2022-020.05194
2022-050.04676
2022-080.04771
2022-110.04479
2023-020.04392
2023-050.04254
2023-080.04113
2023-110.04095
2024-020.04069
2024-050.03788
2024-080.03808
2024-110.03454
2025-020.03603
2025-050.03488
2025-080.03596
2025-110.03386
2026-020.03378
2026-050.03246
2026-080.03046
2026-110.03283

Source: CMS NADAC weekly files, generic rows, monthly median of weekly averages · data as of 2026-11. Figures can change and may contain errors in the source data. Check the original source before relying on them.

Recall records mentioning gabapentin

openFDA enforcement records, by year reported.

20257
20241
20232
20211
20202
20192
20183
20155
20141
20131

25 records since 2012. A record is one product or lot, not one recall event. Combination products that contain gabapentin are included.

What these numbers mean

NADAC is what retail pharmacies pay on average to buy the drug, published by CMS. It does not include rebates and is not what you pay at the counter. ANDA counts include all strengths and forms and applications whose products are now discontinued.

Most recent recall records

Class IIOngoing
Gabapentin capsules
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0031-2026
Class IIOngoing
Gabapentin product
Reason category: Impurities (e.g. nitrosamines)
FDA recall number D-0030-2026
Class IIOngoing
Gabapentin capsules
Reason category: Labeling or packaging error
FDA recall number D-0508-2025
Class IIOngoing
Gabapentin capsules
Reason category: Labeling or packaging error
FDA recall number D-0507-2025
Class IIOngoing
Gabapentin tablets
Reason category: cGMP deviations
FDA recall number D-0320-2025

Not health advice. GxRadar is for general information only. Nothing here is medical, pharmacy, legal or financial advice. Do not start, stop or change any medicine based on this site. Talk to your pharmacist or prescriber about your own situation.

Articles that mention gabapentin

13 GxRadar articles cite or discuss this drug.

GABAPENTIN · NADAC
Price histories · Data story · 5 min

What pharmacies paid for gabapentin, 2013 to 2026

The pharmacy cost of a generic 300 mg gabapentin capsule fell from 5.6 cents in 2013 to a series low of 3.0 cents in September 2026, with a sharp rise in between. The NADAC record and the FDA approvals behind it.

PRICE INDEX · 2014 = 100
Price histories · Data story · 5 min

What pharmacies pay for a month of common generics

Thirty tablets of each of the 10 most-used generics we track cost pharmacies $35.70 in January 2014 and $8.80 in October 2026. That is acquisition cost, and the rest of the price sits on top of it.

Labels & identifiers · Explainer · 6 min

Boxed warnings, FDA's most prominent label warning, explained

What 21 CFR 201.57 requires of a boxed warning, how many prescription labels carry one (about a third, by two counts 14 years apart), and why a generic's box matches the brand's.

GENERIC APPROVALS PER YEAR
Medicare & Medicaid · Data story · 5 min

Generics fill 84.5% of Medicare Part D claims and account for 11.6% of the cost

CMS grand totals for 2013 to 2024 show the generic share of Part D claims rising and the generic share of cost falling, plus a 2024 drop in generic spending that matches a pricing rule change.

The approval pathway · Explainer · 5 min

Pediatric exclusivity and the six months it adds before generics

A brand company that studies its drug in children at FDA's written request can win six more months of protection from generics. How the 1997 incentive works, what it attaches to, and what FDA's own lists show.

Using medicines safely · Explainer · 7 min

Unit-dose and blister packaging, from hospital carts to dose packs

How unit-dose systems spread through US hospitals, what FDA requires on unit-dose and blister labels, the six-month dating rule for repackaged doses, and how blister packs fail.